Omalizumab for Severe Asthma: Beyond Allergic Asthma
المؤلفون المشاركون
Loureiro, C. C.
Amaral, L.
Ferreira, J. A.
Lima, R.
Pardal, C.
Fernandes, I.
Semedo, L.
Arrobas, A.
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-09-17
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Different subsets of asthma patients may be recognized according to the exposure trigger and the frequency and severity of clinical signs and symptoms.
Regarding the exposure trigger, generally asthma can be classified as allergic (or atopic) and nonallergic (or nonatopic).
Allergic and nonallergic asthma are distinguished by the presence or absence of clinical allergic reaction and in vitro IgE response to specific aeroallergens.
The mechanisms of allergic asthma have been extensively studied with major advances in the last two decades.
Nonallergic asthma is characterized by its apparent independence from allergen exposure and sensitization and a higher degree of severity, but little is known regarding the underlying mechanisms.
Clinically, allergic and nonallergic asthma are virtually indistinguishable in exacerbations, although exacerbation following allergen exposure is typical of allergic asthma.
Although they both show several distinct clinical phenotypes and different biomarkers, there are no ideal biomarkers to stratify asthma phenotypes and guide therapy in clinical practice.
Nevertheless, some biomarkers may be helpful to select subsets of atopic patients which might benefit from biologic agents, such as omalizumab.
Patients with severe asthma, uncontrolled besides optimal treatment, notwithstanding nonatopic, may also benefit from omalizumab therapy, although currently there are no randomized double-blind placebo controlled clinical trials to support this suggestion.
However, omalizumab discontinuation according to each patient’s response to therapy and pharmacoeconomical analysis are questions that remain to be answered.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Loureiro, C. C.& Amaral, L.& Ferreira, J. A.& Lima, R.& Pardal, C.& Fernandes, I.…[et al.]. 2018. Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International،Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1125741
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Loureiro, C. C.…[et al.]. Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International No. 2018 (2018), pp.1-10.
https://search.emarefa.net/detail/BIM-1125741
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Loureiro, C. C.& Amaral, L.& Ferreira, J. A.& Lima, R.& Pardal, C.& Fernandes, I.…[et al.]. Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1125741
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1125741
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر